Comparative Pharmacology
Head-to-head clinical analysis: DARAPRIM versus EGATEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DARAPRIM versus EGATEN.
DARAPRIM vs EGATEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Daraprim (pyrimethamine) is a folic acid antagonist that inhibits dihydrofolate reductase (DHFR) in susceptible protozoa, thereby interfering with folate synthesis and blocking DNA synthesis and cell replication. It is synergistic with sulfonamides, which inhibit dihydropteroate synthase in the folate pathway.
Triclabendazole inhibits tubulin polymerization by binding to the colchicine binding site on beta-tubulin, leading to disruption of microtubule formation and paralysis/death of susceptible parasites, particularly Fasciola species.
50 mg orally once daily for 2 days, then 25 mg orally once daily for 4 weeks; for toxoplasmosis, a loading dose of 200 mg orally once daily for 1 day, followed by 50-75 mg orally once daily for 4-6 weeks, with folinic acid 10-25 mg daily.
10 mg/kg orally as a single dose, with food; for fascioliasis, 10 mg/kg orally three times daily for 3 days.
None Documented
None Documented
Terminal elimination half-life is approximately 111 hours (range 54-148 hours) in adults. The long half-life allows weekly dosing for toxoplasmosis treatment.
Terminal elimination half-life: 4-6 hours in healthy adults; prolonged to 8-12 hours in severe hepatic impairment. Clinical context: supports once-daily dosing.
Primarily hepatic metabolism; renal excretion accounts for approximately 30% of elimination as unchanged drug and metabolites. Fecal excretion is minimal (<5%).
Primarily fecal (90% as metabolites); renal excretion of unchanged drug is negligible (<1%).
Category C
Category C
Antiprotozoal Agent
Antiprotozoal Agent